Abstract
血小板は止血に不可欠な血球成分であり，重度の血小板減少症には輸血が行われてきた．iPS（induced pluripotent stem）細胞から製造される血小板は，社会の高齢化に伴う献血ドナー不足や輸血不応症等を解決するものと期待され，巨核球株の樹立や新規薬剤・バイオリアクターの開発によって臨床スケールでの製造が可能となり，臨床応用が始まりつつある．今後は，早期の普及によってiPS細胞応用医療を牽引し，輸血医療を大きく発展させることが期待される．
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
